| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.09 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.083 | 0.6 |